相关实验视频

Updated: Jan 9, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

[用于口腔状细胞癌的诱导化疗与并发化疗和放射性化疗的临床研究]

J Wei¹, K Liu¹, N X Chen¹

¹College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, China National Clinical Research Center for Otolaryngologic Diseases State Key Lab of Hearing Science, Ministry of Education, China Beijing Key Lab of Hearing Impairment Prevention and Treatment, Beijing 100853, China.

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

|December 10, 2025

概括

非手术综合疗法,包括诱导化疗和EGFR抑制剂的化疗放射治疗,对于晚期口腔状细胞癌 (OPSCC) 是有效的. 人类乳头瘤病毒 (HPV) 阳性 (p16+) 患者的生存率明显优于HPV阴性 (p16-) 患者.

科学领域:

在瘤学瘤学.
头部和部手术头部和部手术
癌症治疗方法癌症治疗方法

背景情况:

局部发达的口腔状细胞癌 (OPSCC) 存在重大治疗挑战.
人类乳头瘤病毒 (HPV) 状态越来越被认为是OPSCC的关键预后因素.

研究的目的:

评估高级OPSCC的非手术综合治疗的疗效和安全性.
为了确定HPV状态 (p16表达) 对患者结局的影响.

主要方法:

对152名先进OPSCC患者的回顾性分析,这些患者接受了诱导化疗 (IC) +并发化疗 (CCRT) ±表皮生长因子受体 (EGFR) 抑制剂.
治疗包括尼莫图祖马布,塞图西马布或PD-1免疫疗法. 放射治疗利用了螺旋式断层疗法 (HT) 和强度调节放射疗法 (IMRT).
使用卡普兰-梅尔和考克斯回归分析的生存率;通过CTCAE v5.5评估的不良事件.

主要成果:

两年和三年总生存率分别为86.8%和74.6%;无进展生存率分别为83.5%和73.3%.
与p16-患者 (n=33) 相比,p16+患者 (n=71) 的2年生存率 (98.9%) 和3年生存率 (93.2%) 显著更高 (分别为77.2%和61.4%).
3级口喉粘膜炎发生在83.3%的患者中,通常耐受良好,需要最小的营养支持.

结论:

非手术综合疗法 (IC+CCRT±EGFR抑制剂) 是高级OPSCC的有效治疗方法.
p16+状态与高级OPSCC中优异的生存结果有关.
治疗方案通常被患者容忍得很好.

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...